found Documents: 102

Corporate presentations, Presentations | 30 Jul 2020

Corporate presentation

2 items

Download Presentation (with Appendix) (PDF)Download Chinese Presentation (PDF)

Corporate presentations, Event, Presentations | 1 Jun 2020

ASCO Investor Update

1 item

Press release released: May 29, 2020 (Fri) >> See press release here Presentation webcast & call: June 1, 2020 (Mon) 1pm GMT/ 8am EDT/ 8pm HKT >> Click here for the webcast replay

Download Presentation (PDF)

Presentations, Scientific Publications | 27 Apr 2020

AACR2020: Comparison of Pharmacokinetic Profiles and Safety of Surufatinib in Patients from China and the United States

1 item

Title: Comparison of Pharmacokinetic Profiles and Safety of Surufatinib in Patients from China and the United States Presenter: Arvind Dasari Authors: A Dasari1, S Paulson2, E Hamilton3, J Wang4, M Sung5, G Falchook6, C Tucci7, K

Download Presentation (PDF)

Presentations, Scientific Publications | 27 Apr 2020

AACR2020: A Phase I Trial of Surufatinib plus Toripalimab in Patients with Advanced Solid Tumor

1 item

Title: A Phase I Trial of Surufatinib Plus Toripalimab in Patients with Advanced Solid Tumors Presenter: Yanshuo Cao Authors: M Lu1, Y Cao1, J Gong1, Y Sun2, J Li1, L Shen1. 1 Department of Gastrointestinal Oncology, Key Labor

Download Presentation (PDF)

Presentations, Scientific Publications | 13 Mar 2020

ENETS 2020 : Safety Profile and AESI for Surufatinib in Chinese Patients with Advanced Extra-Pancreatic Neuroendocrine Tumors: Analysis of the Phase 3 SANET-ep Trial

1 item

The previously reported SANET-ep trial (clinicaltrials.gov identifier NCT02588170) demonstrated that surufatinib significantly improves progression-free survival (“PFS”) in patients with advanced extrapancreatic (non-pancreatic) neuroendocrine tu

View Poster

Corporate presentations, Event, Presentations | 3 Mar 2020

2019 Full Year Results

1 item

Announcement released: 12 noon GMT (7am EST / 8pm HKT ) >> See announcement here Presentation webcast & call: 1pm GMT (8am EST / 9pm HKT) >> Click here for the webcast replay To participate by phon

Download Presentation (PDF)

Presentations, Scientific Publications | 6 Feb 2020

The Lancet Oncology: Osimertinib plus Savolitinib in EGFRm+, MET+ NSCLC

Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study Lecia V Sequist;

Corporate presentations, Presentations | 20 Jan 2020

Corporate presentation

1 item

Download Presentation (PDF)

Corporate presentations, Event, Presentations | 15 Jan 2020

38th Annual J.P. Morgan Healthcare Conference

1 item

Location: Westin St. Francis Hotel, San Francisco, CA Presentation Date: Wednesday Jan 15, 2020 Presentation Time: 01:00pm PST (04:00pm EST/09:00pm BST) Audio Recording: Please download the accompanying presentation. [audi

Download Presentation (PDF)

Corporate presentations, Event, Presentations | 13 Nov 2019

Deutsche Bank ADR Virtual Investor Conference (dbVIC)

1 item

Live virtual investor conference. Time: 01:30 pm GMT (09:30 pm HKT/08:30 am EST) >> Click here for the webcast

Download Presentation (PDF)

Corporate presentations, Event, Presentations | 30 Sep 2019

Post-ESMO Surufatinib Update

1 item

Press release released: September 29, 2019 (Sun) >> See press release here Presentation webcast & call: September 30, 2019 (Mon) 2pm CEST (1pm BST/8am EDT/8pm HKT) >> Click here for the webcast replay

Download Presentation (PDF)

Presentations, Scientific Publications | 29 Sep 2019

ESMO 2019: Efficacy and Safety of Surufatinib in Patients with Well-Differentiated Advanced Extrapancreatic NETs

1 item

Title: Efficacy and Safety of Surufatinib in Patients with Well-Differentiated Advanced Extrapancreatic Neuroendocrine Tumors: Results from the Randomized Phase III Study (SANET-ep) Presenting Author: Jianming Xu, Head of th

Download Presentation (PDF)

Presentations, Scientific Publications | 21 Sep 2019

CSCO 2019: Association Between Hand-Foot Skin Reaction (HFSR) and Survival Benefit of Fruquintinib in FRESCO Trial

1 item

Presentation Title : Association Between Hand-Foot Skin Reaction and Survival Benefit of Fruquintinib in FRESCO Trial Presenting Author: Yuxian Bai, Harbin Medical University Cancer Hospital Other Authors: Jin Li, Shukui Qin, Yanho

Download Presentation (PDF)

Presentations, Scientific Publications | 19 Sep 2019

CSCO 2019 : Subgroup Analysis of Patients With Metastatic Colorectal Cancer Treated With Fruquintinib in the FRESCO Trial Who Had Liver Metastasis

1 item

Presentation Title : Subgroup Analysis of Patients With Metastatic Colorectal Cancer Treated With Fruquintinib in the FRESCO Trial Who Had Liver Metastasis Presenting Author: Shukui Qin, Nanjing Chinese Medicine University Affiliated Bay

Download Presentation (PDF)

Presentations, Scientific Publications | 9 Sep 2019

WCLC 2019: Phase III Fruquintinib v.s. Placebo in Advanced Non-Small Cell Lung Cancer (FALUCA)

1 item

MA14.05 - A Randomized Phase III Trial of Fruquintinib Versus Placebo in Patients with Advanced Non-Small Cell Lung Cancer (FALUCA) Venue: IASLC 2019 World Conference on Lung Cancer in Barcelona, Spain Session:MA14 - The Adequate MTarget

Download Presentation (PDF)

Corporate presentations, Event, Presentations | 9 Sep 2019

CLSA Investors' Forum 2019

1 item

Grand Hyatt, Hong Kong

Download Presentation (PDF)

Corporate presentations, Event, Presentations | 30 Jul 2019

2019 Half-Year Financial Results

1 item

Announcement released: 7am BST (2pm HKT/2am EDT) >> See announcement here Presentation webcast & call: 9am BST (4pm HKT/4am EDT) >> Click here for the webcast US conference call: 9am EDT (2pm BST/9pm HKT)

Download Presentation (PDF)

Presentations, Scientific Publications | 1 Jun 2019

Clin Cancer Res: Surufatinib in advanced, well-differentiated neuroendocrine tumors

Surufatinib in advanced well-differentiated neuroendocrine tumors: a multicenter, 3 single-arm, open-label, phase Ib/II trial Jianming Xu, Jie Li, Chunmei Bai, Nong Xu, Zhiwei Zhou, Zhiping Li, Caicun Zhou, Ru Jia, Ming Lu, Yuejuan Cheng, Chenyu Mao

Corporate presentations, Event, Presentations | 31 May 2019

Morgan Stanley Annual China Summit 2019

2 items

Rosewood Beijing

Download English Presentation (PDF)Download Chinese Presentation (PDF)

Corporate presentations, Event, Presentations | 8 May 2019

J.P. Morgan Global China Summit 2019

2 items

China World Summit Wing Hotel, Beijing

Download English Presentation (PDF)Download Chinese Presentation (PDF)

Corporate presentations, Event, Presentations | 11 Mar 2019

2018 Full Year Results

1 item

Announcement released: 7am BST (3pm HKT / 3am EDT) >> See announcement here Presentation webcast & call: 9am BST (5pm HKT / 5am EDT) >> Click here for the webcast US conference call: 9am EDT (1pm BST/9pm HKT

Download Presentation (PDF)

Corporate presentations, Event, Presentations | 7 Jan 2019

37th Annual J.P. Morgan Healthcare Conference

1 item

Location: Westin St. Francis Hotel, San Francisco, CA Presentation Date: Wednesday Jan 9, 2019 Presentation Time: 9:30am PST (12:30pm EST/5:30pm BST) Audio Recording: Please download the accompanying presentation. [audio m

Download Presentation (PDF)

Corporate presentations, Event, Presentations | 27 Jul 2018

2018 Half-Year Financial Results

1 item

Announcement released: 7am BST (2pm HKT/2am EDT) >> See announcement here Presentation webcast & call: 9am BST (4pm HKT/4am EDT) >> Click here for the webcast US conference call: 9am EDT (2pm BST/9

Download Presentation (PDF)

Presentations, Scientific Publications | 26 Jun 2018

JAMA: Fruquintinib vs Placebo in Previously Treated Metastatic Colorectal Cancer

Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer The FRESCO Randomized Clinical Trial Jin Li; Shukui Qin; Rui-Hua Xu; Lin Shen; Jianming Xu; Yuxian Bai; Lei Yang; Yanhong Deng;

Presentations, Scientific Publications | 4 Jun 2018

ASCO 2018: Colorectal cancer Q-TWiST with fruquintinib treatment in FRESCO

1 item

Quality-adjusted time without symptoms or toxicity (Q-TWiST) of patients with metastatic colorectal cancer treated with fruquintinib in FRESCO Presenter: Yu-Xian Bai Other Authors: Hongyan Li, Ning Wang, Xiaojun Guo, Wei Wang, Songhua F

View Poster

Presentations, Scientific Publications | 4 Jun 2018

ASCO 2018: Subgroup analysis by prior anti-VEGF or anti-EGFR target therapy in FRESCO

Presenter: Ruihua Xu Other Authors: Jin Li, Yu-Xian Bai, Yanhong Deng, Lei Yang, Haijun Zhong, Zhendong Chen, Hongming Pan, Weijian Guo, Yongqian Shu, Ying Yuan, Jianming Xu, Lin Shen, Ning Wang, Xin Wang, Haidong Chi, Jack Peng, Y

Presentations, Scientific Publications | 17 Apr 2018

AACR 2018: MET gene copy number gains evaluated by NGS is more predictive than other methods to enrich for papillary RCC patients sensitive to savolitinib

1 item

4541 / 26 - MET gene copy number gains evaluated by NGS is more predictive than other methods to enrich for papillary RCC patients sensitive to savolitinib, a selective MET inhibitor Presenter/Authors M. M. Frigault1, S. Signoretti2, A. Markovets

View Poster

Presentations, Scientific Publications | 23 Mar 2018

ASCPT 2018: Fruquintinib Pharmacokinetics in Humans

1 item

Pharmacokinetics of Fruquintinib in Humans Venue: American Society for Clinical Pharmacology & Therapeutics Annual Meeting in Orlando, Florida, USA Abstract #: PII-116 Authors: Ke Li, Chen Yu, Yanmei Liu, Xiangkun Li, Sumei Xia, Jian Wa

Download Poster Presentation (PDF)

Corporate presentations, Event, Presentations | 12 Mar 2018

2017 Full Year Financial Results

1 item

Announcement released: 7am BST (3pm HKT/3am EDT) » See announcement here Presentation webcast & call: 9am BST (5pm HKT/5am EDT) » Click here for a video of the webcast US conference call: 9am EDT (1pm BST/9pm HKT)

View Presentation (PDF)

Presentations, Scientific Publications | 12 Mar 2018

Journal of Clinical Oncology: Phase II Trial of Fruquintinib in Patients with Advanced Nonsquamous NSCLC

Shun Lu, Jianhua Chang, Xiaoqing Liu, Jianhua Shi, You Lu, Wei Li, Jin-ji Yang, Jianying Zhou, Jie Wang, Tongtong An, Lei Yang, Zhe Liu, Xiangdong Zhou, Mo Chen, Ye Hua and Weiguo Su Abstract Purpose Patients with advanced non‒small-cell lung

Presentations, Scientific Publications | 24 Feb 2018

ACOS 2018: Adverse Events of Special Interest Profiles and Time Courses of Fruquintinib in the FRESCO Trial

1 item

Venue: The 13th International Conference of the Asian Clinical Oncology Society in Chiang Mai, Thailand Abstract #: ABS093 Authors: Jin Li, Shukui Qin, Yuxian Bai, Yanhong Deng, Lei Yang, Zhendong Chen, Haijun Zhong, Rui-hua Xu, Hongming Pan,

Download Slides (PDF)

Presentations, Scientific Publications | 20 Feb 2018

ICTO2018: Phase Ib of Savolitinib and Durvalumab in Renal Cell Carcinoma (CALYPSO)

A Phase Ib Study of Durvalumab (MEDI4736) in Combination with Savolitinib in Patients with Metastatic Renal Cell Carcinoma S Vari1, B Szabados1, A GomezdeLiano1, K Mousa2, L Rammazzo2, A Prendergast2, T Powles1 1 Barts Health NHS Trust, Barts Can

Presentations, Scientific Publications | 17 Oct 2017

WCLC 2017: Phase Ib/II savolitinib plus Iressa® in MET-driven NSCLC

OA 09.06 – A Phase Ib Trial of Savolitinib plus Gefitinib for Chinese Patients with EGFR-Mutant MET-Amplified Advanced NSCLC Jin-Ji Yang, Jian Fang, Y. Shu, J. Chang, G. Chen, J. He, W. Li, X. Liu, N. Yang, Caicun Zhou, J. Huang, L. Yang, A.A. Han

Presentations, Scientific Publications | 17 Oct 2017

WCLC 2017: Phase Ib/II savolitinib plus Tagrisso® in MET-driven NSCLC

OA 09.03 – TATTON Ph Ib Expansion Cohort: Osimertinib plus Savolitinib for Pts with EGFR-Mutant MET-Amplified NSCLC after Progression on Prior EGFR-TKI Myung-Ju Ahn, Ji-Youn Han, Lecia V Sequist, Byoung Chul Cho, J.S. Lee, Sang-We Kim, W. Su, C. T

Presentations, Scientific Publications | 15 Oct 2017

WCLC 2017: Phase II fruquintinib combination with Iressa in NSCLC

JCSE 01.12 – A Phase II study of fruquintinib in combination with gefitinib in stage IIIb/IV NSCLC patients harboring EGFR activating mutations (NCT02976116) Shun Lu, Jianying Zhou, Xiaomin Niu, Mo Chen, Hongyan Yin, Ye Hua, Weiguo Su Venue: IA

Presentations, Scientific Publications | 28 Sep 2017

CSCO 2017: Savolitinib Phase Ib in c-MET Gastric Cancer

1 item

Phase Ib Trial of the Safety and Antitumor Activity of Savolitinib in Advanced Gastric Cancer Patients with Aberrant c-MET Jifeng Feng, Baorui Liu, Tianshu Liu, Nong Xu, Jianming Xu, Yunpeng Liu, Yuxian Bai, Jin Li, Wei Li, Chunmei Bai, Tao Zhang,

Download Slides (PDF)

Presentations, Scientific Publications | 28 Sep 2017

CSCO 2017: Theliatinib Phase I Results

1 item

Novel EGFR TKI Theliatinib: An Open Label, Dose Escalation Phase I Clinical Trial Lin Shen, Li Zhang, Hongyun Zhao, Wenfeng Fang, Jifang Gong Venue: Chinese Society of Clinical Oncology Annual Meeting Session: Esophageal Cancer Presenter: Jif

Download Slides (PDF)

Presentations, Scientific Publications | 27 Sep 2017

CSCO 2017: FRESCO In-Depth Analysis

1 item

In-depth Analysis of the FRESCO Study: a Randomized, Double-blind, Phase III Trial Evaluating the Efficacy and Safety of Fruquintinib in Patients with 3+ Line Advanced Colorectal Cancer Shukui QIN*, Jin LI*, Yuxian BAI, Yanhong DENG, Lei YANG, Zhen

Download Slides (PDF)

Presentations, Scientific Publications | 27 Sep 2017

CSCO 2017: Theliatinib Preclinical Study in Esophageal Cancer

Is EGFR a “feasible” target for advanced esophageal cancer treatment? Rongxin Ren, Shiming Fan, Linfang Wang,Min Cheng, Dongxia Shi, Wei Zhang,Renxiang Tang, Ying Yu, Longxian Jiao, Jun Ni, Haibin Yang, Huaqing Cai,Feng Zhou, Weihan Zhang, Wei

Corporate presentations, Event, Presentations | 16 Sep 2017

The Royal Society of Medicine 15th Medical Innovations Summit

1 item

The Royal Society of Medicine, London, UK Please visit rsm.ac.uk for more information. A video recording of the 20-minute presentation is available. RSM video link Note: there is a 25-second audio error at 2:55.

View Presentation (PDF)

Corporate presentations, Event, Presentations | 31 Jul 2017

2017 Half-Year Financial Results

1 item

Announcement released: 7am BST (2am EDT, 2pm HKT) » See announcement here Presentation webcast & call: 9am BST (4pm HKT) » click here for a video of the webcast US conference call: 9am EDT (2pm BST) » To parti

View Presentation (PDF)

Presentations, Scientific Publications | 23 Jun 2017

Journal of Clinical Oncology: Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced PRCC

Toni K. Choueiri, Elizabeth Plimack, Hendrik-Tobias Arkenau, Eric Jonasch, Daniel Y.C. Heng, Thomas Powles, Melanie M. Frigault, Edwin A. Clark, Amir A. Handzel, Humphrey Gardner, Shethah Morgan, Laurence Albiges, and Sumanta Kumar Pal Abstract Pur

Corporate presentations, Event, Presentations | 21 Jun 2017

Bernstein Conference: China Oncology Day

1 item

Mandarin Oriental, Hong Kong

Download Presentation (PDF)

Presentations, Scientific Publications | 5 Jun 2017

ASCO 2017: Fruquintinib Phase III in Metastatic Colorectal Cancer (FRESCO)

1 item

A randomized, double-blind, placebo-controlled, multi-centered phase III trial comparing fruquintinib versus placebo plus best supportive care in Chinese patients with metastatic colorectal cancer (FRESCO) Venue: American Society of Clinical Oncol

View Presentation Slides (PDF)

Presentations, Scientific Publications | 5 Jun 2017

ASCO 2017: Sulfatinib Phase II in Medullary and Differentiated Thyroid Cancer

1 item

A phase II multicenter trial of the multitargeted kinase inhibitor sulfatinib in advanced medullary thyroid cancer (MTC) and radioiodine (RAI)-refractory differentiated thyroid cancer (DTC) Venue: American Society of Clinical Oncology Annual Meeti

Download Poster Presentation (PDF)

Presentations, Scientific Publications | 4 Apr 2017

AACR 2017: Preclinical evaluation of sulfatinib, a novel angio-immuno kinase inhibitor targeting VEGFR, FGFR1 and CSF-1R kinases

1 item

Preclinical evaluation of sulfatinib, a novel angio-immuno kinase inhibitor targeting VEGFR, FGFR1 and CSF-1R kinases Authors: Jinghong Zhou, Jun Ni, Min Cheng, Na Yang, Junqing Liang, Liang Ge, Wei Zhang, Jianxing Tang, Qiaoling Sun, Fu Li, Jia Hu,

Download Presentation (PDF)

Presentations, Scientific Publications | 3 Apr 2017

AACR 2017: Fruquintinib combinations with targeted therapies or immune checkpoint inhibitors in preclinical tumor models

1 item

Evaluation of fruquintinib, a potent and selective oral VEGFR inhibitor, in combination with targeted therapies or immune checkpoint inhibitors in preclinical tumor models Authors: Yongxin Ren, Qiaoling Sun, Jingwen Long, Shiming Fan, Renxiang Tang,

Download Presentation (PDF)

Corporate presentations, Event, Presentations | 30 Mar 2017

R&D Briefing for Investors 2017

1 item

Introduction The Future of Targeted Cancer Therapy In Lung Cancer Post-POC Portfolio Pre-POC Portfolio Research Strategy Transforming into a Fully Integrated Global Biopharma Wed. Mar 29, 9:30am - South Place Hotel, London, UK

Download Presentation (PDF)

Corporate presentations, Event, Presentations | 13 Mar 2017

2016 Full Year Financial Results

1 item

Announcement released: 7am GMT » See announcement here Webcast presentation & conf call: 9am GMT (5pm HKT) » click here for a video of the webcast (available for six months) » To participate by phone, please u

View Presentation (PDF)

Presentations, Scientific Publications | 9 Mar 2017

ENETS 2017: Sulfatinib Phase Ib/II in Advanced Neuroendocrine Tumors

1 item

An Open-Label Phase Ib/II Study of Sulfatinib in Patients with Advanced Neuroendocrine Tumors (NCT02267967) Authors: J.M. Xu, J. Li, C.M. Bai, N. Xu, Z.W. Zhou, Z.P. Li, C.C. Zhou, W. Wang, J. Li, C. Qi, Y. Hua, W.G. Su Summary: The current Phase

Download Presentation (PDF)

2 3